Ryuichi Okamoto

Tokyo Medical and Dental University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Background and aims Clinicians need data on the responsiveness of ileal strictures of Crohn’s disease (CD) to biologic therapy, yet most trials prioritize mucosal healing. We quantified short‑term changes in ileal strictures under biologic treatment and evaluated their prognostic relevance. Patients and methods In a post hoc analysis of a prospective cohort, consecutive patients with ileal or ileocolonic CD initiating or switching a biologic (anti‑tumor necrosis factor [TNF], ustekinumab [UST], or vedolizumab [VDZ]) underwent segment‑specific endoscopic assessment at baseline and 6 months. The primary outcome was resolution or progression of strictures at 6 months. Secondary outcomes included time‑to‑event analyses for hospitalization and surgery. Results Among the 170 patients, the 6‑month stricture resolution and progression rates were 30.9% and 15.7%, respectively. There were no significant differences in stricture dynamics between anti‑TNF agents, UST, and VDZ (P = .443 for resolution and P = .167 for progression). Baseline strictures did not predict outcomes; however, strictures present at 6 months were associated with higher risks of hospitalization (P = .006) and surgery (P = .024), particularly when located in the non-terminal ileum. Clinical, biochemical, and endoscopic activity improved overall during follow‑up. Conclusions The 6‑month stricture status, especially non-terminal ileal disease, carried prognostic significance. Because stricture dynamics did not differ across biologic classes, the presence of strictures alone should not constrain agent selection.

Year:

2026

Introduction: Immune-related adverse events (irAEs), which occur due to loss of immune tolerance, represent a significant challenge when using immune checkpoint inhibitors (ICIs). As the indications for ICIs continue to expand, the incidence of irAEs has been increasing. Immune-mediated diarrhea and colitis (IMDC) is one of the most frequent irAEs. Although important for the management of IMDCs, colonoscopy is highly invasive for patients with cancer, and development of noninvasive alternatives is needed. Methods: We prospectively enrolled patients diagnosed with IMDC between May 2019 and May 2025, and a total of 34 patients were included in the final analysis. Blood and stool samples were collected, and biomarker levels were measured. Endoscopic activity was defined as a Mayo Endoscopic Subscore of ≥2, as evaluated during colonoscopy. The relationship of each biomarker with endoscopic activity was examined using Spearman’s rank correlation and receiver operating characteristic curve analysis. Results: Fecal calprotectin (FC), fecal lactoferrin (FL), and fecal immunochemical test (FIT) were significantly correlated with the Mayo Endoscopic Subscore, with correlation coefficients of 0.50, 0.51, and 0.74, respectively. These biomarkers effectively detected endoscopic activity, with high area under the curve values of 0.79, 0.81, and 0.94, respectively. Furthermore, certain combinations of fecal biomarkers enhanced accuracy, as demonstrated by FC (+) or FIT (+), which achieved a sensitivity of 95.5% and a specificity of 75.0%. Conclusion: Fecal biomarkers were correlated with endoscopic activity and effectively identified patients with endoscopically active IMDC. Our findings suggest that these biomarkers may be valuable tools for the diagnosis and assessment of treatment response in IMDC.

Year:

2025

Introduction: No real-world studies have compared efficacy of ustekinumab (UST) and risankizumab (RZB) for the treatment of Crohn’s disease (CD). Methods: We retrospectively collected the data of patients with CD treated with UST or RZB between May 2017 and March 2024 at the Institute of Science Tokyo and analyzed clinical remission rate at weeks 8 and 28 using Harvey-Bradshaw Index (HBI), with remission defined as a HBI ≤4. Result: A total of 111 patients who were treated with UST and 29 patients treated with RZB were included in the analysis. RZB had higher efficacy both at weeks 8 (82.8% vs. 62.2%, p = 0.0465) and 28 (79.3% vs. 56.8%, p = 0.0321) than UST in the full study cohort, and at weeks 8 (55.6% vs. 18.4%, p = 0.0352) and 28 (66.7% vs. 18.4%, p = 0.0083) in the patients with clinically active disease and anti-TNFα exposed patients. During the observation period, 1 patient with RZB (3.45%) experienced an adverse event that required hospitalization, and 1 patient in the UST group (0.900%) experienced an adverse event that led to treatment discontinuation. Conclusion: RZB may offer greater short-term efficacy than UST, with an acceptable safety profile in real-world settings.

Year:

2025

Plasticity is a central mechanism underlying the robust regenerative capacity of the intestinal epithelium. Two major plasticity have been described: spatial plasticity, in which differentiated cells revert to crypt base columnar cells (CBCs), and fetal reversion into revival stem cells (revSCs). However, the relationship among these two stem cell populations and differentiated cells remains to be clarified. Here, we demonstrated the bidirectional interconversion between CBCs and revSCs. Using lineage tracing, injury models and villus culture, we show that absorptive enterocytes can reprogram into revSCs and regenerate CBCs. These findings position fetal reversion as an entry point to spatial plasticity, establishing a regenerative hierarchy where CBCs, revSCs, and enterocytes collectively orchestrate intestinal repair. Furthermore, we identified revSCs as a highly stress-tolerant stem cell population, whose emergence is crucial for preserving the stem cell pool. Our results establish fetal reversion as a cellular escape mechanism safeguarding epithelial regeneration under inflammatory conditions.

Year:

2025

Background The importance and pathophysiology of transmural healing in patients with Crohn’s disease [CD] remains to be verified. We aimed to examine the association between serum concentrations of biologics and transmural remission evaluated via magnetic resonance enterography [MRE]. Methods We enrolled patients with CD who received maintenance biologics 1 year after induction and prospectively followed up for at least 1 year after baseline laboratory, endoscopic and MRE examination. We evaluated the relationship between baseline factors including the presence of transmural remission and patient prognosis, as well as between serum concentrations and transmural remission. Results We included 134 patients, of whom 65, 31, 27 and 11 received infliximab, adalimumab, ustekinumab and vedolizumab, respectively. Those who achieved transmural remission showed a lower risk of hospitalization and surgery than those who did not achieve remission [p < 0.01]. Adjusted hazard ratios of transmural remission for predicting hospitalization and surgery were 0.11 and 0.02, respectively, which were lower than those of clinical remission, biochemical remission and endoscopic remission. Regarding serum concentrations, the median concentration was higher in patients with transmural remission than in patients with transmural activity for all agents [p < 0.01 for infliximab, p = 0.04 for adalimumab, p < 0.01 for ustekinumab, p = 0.08 for vedolizumab]. Conclusions Transmural remission was the best predictor for prognosis in CD patients who received maintenance biologic therapy. High drug concentration levels were associated with transmural remission confirmed via MRE.

Year:

2022

Collaborators (5)

Toshimitsu Fujii

Tokyo Institute of Technology

JAPAN
View details

Sakura Kirino

Project researcher

Tokyo Institute of Technology

JAPAN
View details

Shiro Yui

Tokyo Institute of Technology

JAPAN
View details

Kento Takenaka

Tokyo Medical and Dental University

JAPAN
View details

Hans Clevers

Prof. dr

Utrecht University

NETHERLANDS
View details